Physician profile
Adeel Amir
NPI 1558712489
$2,669.49
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $646 · 2021: $1,161 · 2022: $550.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $429.38 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $339.97 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $279.33 | 2019-2022 | |
| Glaxosmithkline, LLC. | $243.59 | 2019-2021 | |
| Gilead Sciences, INC. | $188.85 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $185.84 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $129.14 | 2020-2022 | |
| Amarin Pharma, INC. | $123.26 | 2021-2022 | |
| Amgen INC. | $116.42 | 2020-2022 | |
| Abbvie INC. | $103.99 | 2021-2022 | |
| Novo Nordisk INC | $92.79 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $57.36 | 2021-2022 | |
| Pfizer INC. | $51.88 | 2021 | |
| Novartis Pharmaceuticals Corporation | $47.36 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.86 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $36.73 | 2021 | |
| Esperion Therapeutics, INC. | $35.24 | 2021 | |
| Upsher-Smith Laboratories LLC | $33.69 | 2021-2022 | |
| Bausch Health US, LLC | $32.56 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $21.50 | 2021 | |
| Astellas Pharma US INC | $18.02 | 2021 | |
| Nevro Corp. | $17.93 | 2022 | |
| Currax Pharmaceuticals LLC | $17.23 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.49 | 2021 | |
| Allergan, INC. | $14.08 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adeel Amir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.